Cardiovascular event risk reduction in obesity

Cardiovascular event risk reduction in obesity refers to the therapeutic mitigation of major adverse cardiovascular events—predominantly cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in individuals with excess adiposity, particularly those with established cardiovascular disease Consequently, this clinical state represents a high-risk vascular vulnerability where targeting adiposity-driven metabolic derangements aims to decelerate atherogenesis, preserve coronary and ...

Cardiovascular event risk reduction in obesity refers to the therapeutic mitigation of major adverse cardiovascular events—predominantly cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in individuals with excess adiposity, particularly those with established cardiovascular disease

Obesity directly impairs the cardiovascular system through hemodynamic alterations, ectopic adipose deposition, chronic low-grade systemic inflammation, and endothelial dysfunction, while indirectly compounding injury via comorbid hypertension, atherogenic dyslipidemia, and insulin resistance Consequently, this clinical state represents a high-risk vascular vulnerability where targeting adiposity-driven metabolic derangements aims to decelerate atherogenesis, preserve coronary and cerebral perfu...

Obesity directly impairs the cardiovascular system through hemodynamic alterations, ectopic adipose deposition, chronic low-grade systemic inflammation, and endothelial dysfunction, while indirectly compounding injury via comorbid hypertension, atherogenic dyslipidemia, and insulin resistance